gdc
PSSGuide_2021
Pancreatic Cancer

Drugs for Pancreatic Cancer

Find financial assistance programs available for pancreatic cancer drugs.

Abraxane (paclitaxel protein-bound particles; albumin-bound)

Drug company: Bristol Myers Squibb
800-861-0048

Abraxane is a microtubule inhibitor used, in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Abraxane:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Abraxane. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Abraxane, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Lynparza (olaparib) Capsules/Tablets

Drug company: AstraZeneca
844-275-2360

Lynparza is a PARP inhibitor used for the maintenance treatment of patients with metastatic pancreatic cancer and deleterious or suspected deleterious germline BRCA mutation, as detected by an FDA-approved test, in adults whose disease had not progressed after 16 weeks or more of platinum-based chemotherapy in the first-line setting.

AstraZeneca offers 2 financial assistance programs for patients who have been prescribed Lynparza:

Lynparza Co-pay Savings Program

The patient’s out-of-pocket costs may vary, but this program aims for eligible patients to pay $0 per month for Lynparza, with a maximum out-of-pocket savings of $26,000 annually. This program has no income requirements, but eligible patients must have private health insurance that partially covers the medication costs for Lynparza.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year and must be unable to enroll in Medicare limited income subsidy.

Patients with Medicare Part B coverage should call 800-292- 6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Lynparza (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Onivyde (irinotecan liposome injection)

Drug company: Ipsen
866-435-5677

Onivyde is a topoisomerase inhibitor used, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic pancreatic cancer whose disease has progressed after treatment with Gemzar.

Ipsen Cares offers 2 financial assistance programs for patients using Onivyde:

Onivyde Copay Program

Eligible patients with private insurance will pay $0 per order of Onivyde, with a maximum annual benefit of $20,000.

Ipsen Cares Patient Assistance Program

Uninsured patients who meet the income criteria may be eligible to receive Onivyde at no cost.

Tarceva (erlotinib) Tablets

Drug company: Genentech
866-422-2377

Tarceva is a kinase inhibitor used, in combination with Gemzar, for the treatment of patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy.

Genentech Oncology offers 2 financial assistance program for patients using Tarceva:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription of Tarceva, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tarceva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Table. Drugs Prescribed for Pancreatic Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Lynparza (olaparib)
  • Drug company
  • AstraZeneca
  • Indication
  • Maintenance treatment of patients with metastatic pancreatic cancer and deleterious or suspected deleterious germline BRCA mutation, as detected by an FDA-approved test, in adults whose disease had not progressed after 16 weeks or more of platinum-based chemotherapy in the first-line setting
  • Patient support services
  • Lynparza Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    800-292-6363



Share this:

Last modified: April 1, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests